

[View this email in your browser](#)



**RELIVE flash**

No.6 - April 2023

**Meeting of the RELIVE Steering Committee during SIOPEL 2023 in Utrecht**

Usually the Steering Committee (StC) meets every two to three months by videoconference. Now the StC convened for the first time in person on March 22, just prior to the SIOPEL group meeting held at the Princes Máxima Centrum in Utrecht, NLD.



The remit of the StC is to supervise the progress of the study and to advise the team in Geneva about actions to take.

Marc Ansari, international chairman of the project, as well as the team consisting of Aurore Britan, Fabienne Toutain and Rudolf Maibach informed the members about the status of the study as follows:

- The study has been activated in the following countries: Canada, Germany, Hong Kong, Italy, Japan, The Netherlands, Poland, Spain, Switzerland and USA
- Activation is ongoing in Australia/New Zealand, Belgium, France, Ireland and UK
- The study aims to document a total of 300 patients; 162 patients have been registered as of February 2023; 126 are marked as complete in the REDCap database, 36 records are still incomplete. The patients have been entered by the following sites/countries:

	Complete	Incomplete
Prinses Maxima Centrum, Netherlands	34	
Hospital for Sick Children, Toronto, Canada	31	
Japan (11 institutions)	28	3
Hong Kong Children's Hospital	24	25
Málaga and Sevilla, Spain	6	
Gdansk, Poland		3
Geneva, Lausanne, Zurich, Switzerland	3	3
Istituto Nazionale Tumori, Milano, Italy		2

Allison O'Neill from Dana Farber Cancer Institute reported on the finalisation of the manuscript *The RELIVE Consortium for Relapsed or Refractory Pediatric Liver Tumors: An International Paradigm Towards Sourcing Data for Rare Diseases*. This paper describes the RELIVE project, and will also give an exhaustive overview of currently available evidence on treatment and outcome for relapsed or progressed patients. It will be submitted shortly for publication.

The StC discussed the timelines of the project; the activation of participating sites and countries has taken longer than anticipated. The goal is now to complete the final analysis in about one year from now. **Milestones** until then have been decided as follows:

All data entered:	October 2023
All queries issued by central data management answered:	December 2023
Statistical analysis:	January-March 2024
Final report:	June 2024

For all participating sites and countries, this means that they are kindly asked to identify eligible patients now, to enter complete information for these patients, and to respond promptly to queries issued by central data management. The team in Geneva thanks you for your continued efforts!

A question was raised on how best to record the details of chemotherapy administered to patients. We will address this issue shortly and distribute guidelines to all of you.

**RELIVE people**

**Keith Cheung, Program at McMaster University, Canada**

My name is Keith Cheung and I am currently finishing my final year in the Biology and Pharmacology co-op program at McMaster University. This past summer, I was given the opportunity to work with Dr. Baertschiger and his amazing team at The Hospital for Sick Children for my co-op placement/summer research student program.



Here I was able to get involved with the RELIVE registry project. It was my task to gather, coordinate, and analyze the information related to patients with relapsed or refractory hepatoblastoma or hepatocellular carcinoma. Through this, not only have I learnt so many eye-opening facts about these diseases, but also how to read and analyze electronic medical records and the significance of retrospective data collection.

We have been able to identify thirty-one patients who satisfy the eligibility criteria and have successfully entered them into the REDCap database. I was able to analyze our local outcome and did identify some interesting findings. I am very proud to be involved in this and look forward to seeing the results of this project on a global level.

